Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Download Publication
28 Jan 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

22 Apr 2021

Case Study – Pre-Clinical Respiratory Research with PADA

Case Studies, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
25 Mar 2021

Intranasal Immunization: Promises and Challenges

Webinars, Pharmaceutical, Sustainability, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
19 Mar 2021

Otimização de processos no desenvolvimento de produtos inalatórios orais e nasais.

Webinars, Pharmaceutical, Product Solutions

Read More
27 Jan 2021

COVID 19: Drug Delivery Options to Succeed Sooner

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 16 17 18 19 20 25
Back To Top